Y-Intercept (HK)’s Elevation Oncology ELEV Stock Holding History

Y-Intercept (HK)’s Portfolio ELEV Stock Details ELEV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-14,016	Closed	-$5.14K	–	1688
2025 Q2	$5.14K	Buy	+14,016	New	+$4.68K	﹤0.01%	1586
2024 Q2	–	Sell	-21,805	Closed	-$112K	–	1517
2024 Q1	$112K	Buy	+21,805	New	+$70.6K	0.01%	1267

Other funds holding ELEV

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Y-Intercept (HK)'s ELEV Position: Q3 2025 in Review

Y-Intercept (HK) sold out of Elevation Oncology (ELEV) in Q3 2025, closing a stake of 14,016 shares — an estimated $5.14K sold.

Y-Intercept (HK) first reported a position in ELEV in Q1 2024 and held it in 2 quarters. The position peaked at $112K in Q1 2024. 1 fund tracked by Wall St. Rank holds ELEV as of Q3 2025.

Y-Intercept (HK) reported no remaining Elevation Oncology position as of Q3 2025 after selling out during the quarter.
Y-Intercept (HK) sold 14,016 Elevation Oncology shares in Q3 2025, an estimated $5.14K.
Y-Intercept (HK) first reported a position in Elevation Oncology in Q1 2024 and held it in 2 quarters.
Y-Intercept (HK)'s Elevation Oncology position peaked at $112K in Q1 2024.
1 fund tracked by Wall St. Rank held Elevation Oncology as of Q3 2025.

Based on Y-Intercept (HK)'s 13F filing for Q3 2025, filed 31 Oct 2025.